Xenon Pharmaceuticals Inc.

Novartis Ag

Novartis Pharma Gmbh

Vishnumurthy Kodumuru

Rajender Kamboj

Shaoyi Sun

Zaihui Zhang

Shifeng Liu

Serguei Sviridov

Jianmin Fu

Duanjie Hou

Vandna Raina

Nagasree Chakka

Heinz W Gschwend

Melwyn A Abreo

Michael D Winther

Wenbao Li

Sultan Chowdhury

Natalia Pokrovskaia

Natalie Alysia Dales

Chi Tu

Julia Fonarev

Mark W Holladay

Daniel F Harvey

Mehran Seid Bagherzadeh

Mikhail Kondratenko

Mikhail A Chafeev

Jian-Min Fu

Cindy J Hudson

Kashinath Sadalapure

Qi Jia

Richard Masten Fine

Boris Klebansky

Mark Gray-Keller

Sengen Sun

Mehran Bagherzadeh

Robert Fraser

Shifeng Lui

Mikhail A Kondratenko

Jian-min Fu

Kashinath Sadalupure

Sun Shaoyi

Michael Winther

Heinz Gschwend

The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

Organic compounds

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I), where V, W, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. 

Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): 

Pyridyl derivatives and their use as therapeutic agents

SCD1 inhibitors triazole and tetrazole compounds

A method of treating an SCD-mediated disease or condition in a mammal, preferably a human, includes administering to a mammal a compound of formula (I): 

Pyridazine derivatives and their use as inhibitors of stearoyl-CoA desaturase-1 activity in a mammal

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, J, K, W, V, R, R, R, R, R, R, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. 

Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors

Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels

Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes

Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agents

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, R, R, R, R, R, R, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Substituted pyridazines as stearoyl-CoA desaturase inhibitors

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): Formula (I) where x, y, G, J, L, M, V, W, R, R, R, R, R, R, R, R, R, R, and Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase

Growing community of inventors

Burnaby, Canada

Vishnumurthy Kodumuru